Fig. 3From: A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational studyValidation of the scoring system in the second set of 228 patients from five hospitals. There were no significant differences between the prior rates of good response or non-response in the tocilizumab (TCZ) and TNF inhibitor (TNF-i) groups. Patients with a score of 2 or more points (48.1% of the TCZ group and 49.5% of the TNF-i group) had a significantly higher rate of good response and a lower rate of non-response to TCZ treatment compared with TNF-i treatment. This tendency became remarkable in patients with 3 or more points (24.8% of the TCZ group and 29.3% of the TNF-i group). In contrast, if the score was 1 or less (51.9% of the TCZ group and 50.5% of the TNF-i group), a TNF-i may be preferable because a higher rate of good response and a lower rate of non-response were observed in the TNF-i group compared with the TCZ group, although these differences were not significant: *p < 0.05, **p < 0.01. N.S. not significantBack to article page